My professional career has been focused on developing new therapeutics and diagnostics for infectious diseases with unmet medical needs. My expertise is on advancing new anti-infective and anti-cancer drugs from target selection through lead optimization and clinical candidate nomination. As the lead principal investigator on NIH- and DoD-funded research programs, I have developed new classes of therapeutic compounds, as well as new technologies that accelerate drug discovery. This includes screening assay design, high-throughput screening, hit-to-lead identification and lead optimization. Currently, I'm the Director of the Discovery Technologies group at SRI International, where I oversee the finances, operations, business development and strategic planning for a group of multidisciplinary scientists. Accomplishment highlights:• Developing a new class of anti-TB drugs with the potential to shorten the length of therapy and treat multi-drug resistant infections• Developing a simple, inexpensive high-throughput screening assay against the antibiotic drug target gyrase B• Identifying antiviral compounds from drug re-purposing screens with activity against Ebola virus in animal models• Developing a rapid bacterial diagnostic test that can simultaneously determine the type of bacteria and its drug susceptibility profile from a minimal sample